KR910002562B1 - 피페리딘 유도체의 제조방법 - Google Patents

피페리딘 유도체의 제조방법 Download PDF

Info

Publication number
KR910002562B1
KR910002562B1 KR1019860011334A KR860011334A KR910002562B1 KR 910002562 B1 KR910002562 B1 KR 910002562B1 KR 1019860011334 A KR1019860011334 A KR 1019860011334A KR 860011334 A KR860011334 A KR 860011334A KR 910002562 B1 KR910002562 B1 KR 910002562B1
Authority
KR
South Korea
Prior art keywords
formula
group
substituted
piperidine derivative
acid imide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019860011334A
Other languages
English (en)
Korean (ko)
Other versions
KR870005994A (ko
Inventor
하찌로오 스기모도
다까하루 나까무라
유다까 쓰찌야
히로유끼 스꾸미
구니조오 히구라시
노리오 가리베
요시하루 야마니시
히로오 오구라
신 아라끼
아쓰히꼬 구보다
미찌꼬 오오다께
기요미 야마쓰
Original Assignee
에자이 가부시끼가이샤
나이또오 유우지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 가부시끼가이샤, 나이또오 유우지 filed Critical 에자이 가부시끼가이샤
Publication of KR870005994A publication Critical patent/KR870005994A/ko
Application granted granted Critical
Publication of KR910002562B1 publication Critical patent/KR910002562B1/ko
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
KR1019860011334A 1985-12-27 1986-12-27 피페리딘 유도체의 제조방법 Expired KR910002562B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP60-293885 1985-12-27
JP29388585 1985-12-27

Publications (2)

Publication Number Publication Date
KR870005994A KR870005994A (ko) 1987-07-08
KR910002562B1 true KR910002562B1 (ko) 1991-04-26

Family

ID=17800410

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860011334A Expired KR910002562B1 (ko) 1985-12-27 1986-12-27 피페리딘 유도체의 제조방법

Country Status (13)

Country Link
US (7) US4849431A (cg-RX-API-DMAC7.html)
EP (1) EP0229391B1 (cg-RX-API-DMAC7.html)
JP (2) JP2597559B2 (cg-RX-API-DMAC7.html)
KR (1) KR910002562B1 (cg-RX-API-DMAC7.html)
AT (1) ATE78813T1 (cg-RX-API-DMAC7.html)
AU (1) AU600458B2 (cg-RX-API-DMAC7.html)
CA (1) CA1279317C (cg-RX-API-DMAC7.html)
DE (1) DE3686248T2 (cg-RX-API-DMAC7.html)
DK (1) DK623586A (cg-RX-API-DMAC7.html)
ES (1) ES2044836T3 (cg-RX-API-DMAC7.html)
GR (1) GR3005315T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ218786A (cg-RX-API-DMAC7.html)
PH (1) PH23739A (cg-RX-API-DMAC7.html)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3563964D1 (en) * 1984-10-16 1988-09-01 Synthelabo Piperidine derivatives, their preparation and their therapeutical application
DE3531658A1 (de) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
DE3779991T2 (de) * 1986-09-08 1993-02-04 British Tech Group Dioxopiperidin-derivate enthaltende anxiolytische zusammensetzungen.
JP2573195B2 (ja) * 1986-09-30 1997-01-22 エーザイ株式会社 環状アミン誘導体
EP0294183B1 (en) * 1987-06-02 1994-03-30 Ajinomoto Co., Inc. Use of ethylamine derivatives as antihypertensive agents
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4791121A (en) * 1987-11-02 1988-12-13 The Boc Group, Inc. 4-phenyl-4-(N-(phenyl)amido) piperidine derivatives and pharmaceutical compositions and method employing such compounds
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
FI892362L (fi) * 1988-06-01 1989-12-02 Eisai Co Ltd Buten- eller propensyraderivat.
US5177089A (en) * 1988-06-01 1993-01-05 Eisai Co., Ltd. Butenoic or propenoic acid derivative
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
JP2969359B2 (ja) * 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
JP2931986B2 (ja) * 1989-02-17 1999-08-09 武田薬品工業株式会社 アラルキルアミン誘導体
FR2644786B1 (fr) * 1989-03-21 1993-12-31 Adir Cie Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5356891A (en) * 1989-09-22 1994-10-18 Witiak Donald T Phenylalkyl amine derivatives having anti-ischaemic activity
US5356906A (en) * 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
EP0497843A4 (en) * 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
US5206240A (en) * 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
US5428043A (en) * 1990-02-08 1995-06-27 Pfizer Inc. Tricyclic-cyclic amines as novel cholinesterase inhibitors
JP3280040B2 (ja) * 1990-03-26 2002-04-30 武田薬品工業株式会社 アミノベンゼン化合物
US5580883A (en) * 1990-03-26 1996-12-03 Takeda Chemical Industries, Ltd. Aminobenzene compounds to prevent nerve cell degradation
US5169855A (en) * 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
US5202318A (en) * 1990-05-14 1993-04-13 Syntex (U.S.A.) Inc. Tricyclic compounds acting at serotonin receptor subtypes
JP2807577B2 (ja) * 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
FR2664592B1 (fr) * 1990-07-10 1994-09-02 Adir Nouveaux derives de la piperidine, de la tetrahydropyridine et de la pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IE912759A1 (en) * 1990-08-06 1992-02-12 Smith Kline French Lab Compounds
US5118691A (en) * 1990-09-20 1992-06-02 Warner-Lambert Co. Substituted tetrahydropyridines as central nervous system agents
US5240934A (en) * 1990-10-19 1993-08-31 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5190951A (en) * 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
TW197435B (cg-RX-API-DMAC7.html) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
JP2671059B2 (ja) * 1990-11-30 1997-10-29 富士レビオ株式会社 ナフトエ酸誘導体
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
FR2672888B1 (fr) * 1991-02-14 1994-02-04 Fabre Medicament Pierre Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
JP3026845B2 (ja) * 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
US5162341A (en) * 1991-02-22 1992-11-10 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists for treatment of amphetamine abuse
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
PL171914B1 (pl) * 1991-03-28 1997-06-30 Eisai Co Ltd Sposób wytwarzania pochodnych aminy heterocyklicznej PL PL PL PL PL PL PL
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5120748A (en) * 1991-06-28 1992-06-09 Warner-Lambert Company Substituted 1,2,3,6-tetrahydropyridines as central nervous system agents
FR2681319B1 (fr) * 1991-09-12 1995-02-17 Synthelabo Derives de 1-(phenoxyalkyl)piperidine, leur preparation et leur application en therapeutique.
US5389631A (en) * 1991-10-29 1995-02-14 Merck & Co., Inc. Fibrinogen receptor antagonists
TW219935B (cg-RX-API-DMAC7.html) * 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
US5462934A (en) * 1992-03-09 1995-10-31 Takeda Chemical Industries Condensed heterocyclic ketone derivatives and their use
TW218875B (cg-RX-API-DMAC7.html) * 1992-03-09 1994-01-11 Takeda Pharm Industry Co Ltd
ATE194982T1 (de) * 1992-04-24 2000-08-15 Takeda Chemical Industries Ltd Benzoxazepin-derivate als cholinesterase- inhibitoren
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
ES2043557B1 (es) * 1992-06-04 1994-07-01 Ferrer Int Procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina.
US5441952A (en) * 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
US5334596A (en) * 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
ES2066721B1 (es) * 1993-05-18 1996-02-16 Ferrer Int Nuevos compuestos derivados de la piridina 1,4-disustituida.
US5397791A (en) * 1993-08-09 1995-03-14 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4335718A1 (de) * 1993-10-20 1995-04-27 Merck Patent Gmbh Cyclische Aminderivate
US5821241A (en) * 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists
IL112764A0 (en) * 1994-03-18 1995-05-26 Ferrer Int New chromene derivatives
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
US5567718A (en) * 1994-08-11 1996-10-22 Hoechst Marion Roussel Inc. 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors
US5859295A (en) * 1994-12-05 1999-01-12 University Of Kentucky Research Foundation Canavanine analogs and their use as chemotherapeutic agents
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) * 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
WO1996022280A1 (de) * 1995-01-18 1996-07-25 Bayer Aktiengesellschaft N-substituierte-1-acylaminoalkyl piperidine zur behandlung von cerebralen störungen und depressionen
US5719144A (en) * 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5852045A (en) * 1995-10-19 1998-12-22 Merck & Co., Inc. Fibrinogen receptor antagonists
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) * 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
US5981584A (en) * 1997-02-06 1999-11-09 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US7085775B2 (en) * 1997-04-09 2006-08-01 Sidewinder Holdings Ltd. Database method and system for conducting integrated dispatching
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
US6900228B1 (en) 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
HUP0104493A3 (en) 1998-09-30 2002-12-28 Takeda Pharmaceutical Drugs for improving vesical excretory strength
ATE386720T1 (de) 1998-11-20 2008-03-15 Hoffmann La Roche Piperidin ccr-3 rezeptor-hemmer
US6677330B1 (en) 1999-03-03 2004-01-13 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
WO2001052839A1 (en) 2000-01-24 2001-07-26 Mruk Jozef S Use of flavone 8-acetic acid in vascular and cardiovascular interventions and acute coronary syndromes
US7812035B2 (en) 2001-12-11 2010-10-12 Sepracor Inc. 4-substituted piperidines, and methods of use thereof
NZ546991A (en) 2003-11-20 2010-01-29 Janssen Pharmaceutica Nv 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors
NZ546990A (en) 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
JP4806353B2 (ja) * 2003-12-05 2011-11-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼインヒビターとしての６−置換２−キノリノンおよび２−キノキサリノン
US7259155B2 (en) * 2004-05-05 2007-08-21 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivatives
EP1600447A1 (en) * 2004-05-28 2005-11-30 Neuropharma S.A.U. Butyrylcholinesterase selective inhibitors
CA2568835C (en) 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
JP5100376B2 (ja) * 2004-06-30 2012-12-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキナゾリンジオン誘導体
KR101188688B1 (ko) 2004-06-30 2012-10-09 얀센 파마슈티카 엔.브이. Ｐａｒｐ 저해제로서의 퀴나졸린디온 유도체
WO2006003147A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
KR20070091038A (ko) * 2004-12-24 2007-09-06 프로시디온 리미티드 Ｇ-단백질 결합 수용체(ｇｐｒ116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도
MX2008002014A (es) * 2005-08-15 2008-03-27 Hoffmann La Roche Derivados de piperidina y piperazina como antagonistas de p2x3.
ZA200904826B (en) * 2007-01-03 2010-09-29 Cortex Pharma Inc 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
DK2271626T3 (en) 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
WO2009118384A1 (en) 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
CN109134350A (zh) * 2017-06-13 2019-01-04 中国药科大学 多奈哌齐－bht杂合体、其制备方法及其用于治疗阿尔茨海默症
CN117551076A (zh) * 2023-11-10 2024-02-13 河南应用技术职业学院 苯并异喹啉-1,3(2h)-二酮衍生物、其制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
US3729270A (en) * 1970-09-19 1973-04-24 Tsukasa Felt Shoji Kk Writing nib
GB1507462A (en) * 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US4158060A (en) * 1974-12-18 1979-06-12 Synthelabo 2-Methoxy-benzamide derivatives
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4360531A (en) * 1981-04-09 1982-11-23 The Upjohn Company Substituted cycloalkanes
US4559343A (en) * 1982-09-07 1985-12-17 Alcon Laboratories, Inc. Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
US4604393A (en) * 1984-01-30 1986-08-05 Cornu Pierre Jean Phenyloxoalkyl piperidines and the pharmaceutical compositions containing them
US4810703A (en) * 1984-10-19 1989-03-07 A. H. Robins Company, Incorporated 1-((aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl)-alpha, alpha-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
DE3541428A1 (de) * 1985-11-23 1987-05-27 Hoechst Ag Neue basisch substituierte pyridinverbindungen, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
US5041547A (en) * 1986-08-28 1991-08-20 Appleton Papers Inc. Chromogenic substituted 4,7-diazaphthalides
US4791112A (en) * 1987-02-02 1988-12-13 The Boc Group, Inc. N-heterocyclic-N-(4-piperidyl)amides and pharmaceutical compositions and methods employing such compounds

Also Published As

Publication number Publication date
CA1279317C (en) 1991-01-22
PH23739A (en) 1989-11-03
KR870005994A (ko) 1987-07-08
JP2597559B2 (ja) 1997-04-09
JPH08333255A (ja) 1996-12-17
AU6690686A (en) 1987-07-02
EP0229391B1 (en) 1992-07-29
DE3686248T2 (de) 1992-12-17
US5118684A (en) 1992-06-02
US5654306A (en) 1997-08-05
NZ218786A (en) 1989-01-06
AU600458B2 (en) 1990-08-16
DK623586A (da) 1987-06-28
ES2044836T3 (es) 1994-01-16
JPS62234065A (ja) 1987-10-14
GR3005315T3 (cg-RX-API-DMAC7.html) 1993-05-24
US5424318A (en) 1995-06-13
US4942169A (en) 1990-07-17
US4849431A (en) 1989-07-18
EP0229391A1 (en) 1987-07-22
ATE78813T1 (de) 1992-08-15
US5306720A (en) 1994-04-26
US5039681A (en) 1991-08-13
DE3686248D1 (de) 1992-09-03
DK623586D0 (da) 1986-12-22
JP2716965B2 (ja) 1998-02-18

Similar Documents

Publication Publication Date Title
EP0229391B1 (en) Piperidine derivate, its use and pharmaceutical composition containing it
US6008231A (en) N-substituted indole-3 glyoxylamides having anti-asthmatic antiallergic and immunosuppressant/immuno-modulating action
CN106928211B (zh) 用于治疗代谢障碍的甲酰胺化合物
JP2650537B2 (ja) 縮合複素環誘導体
US4656174A (en) Quinoline therapeutic agents
JPH08509967A (ja) 血小板凝集抑制剤としての複素環式化合物
CS240954B2 (en) Preparation method of 1,2-dihydropyridines
KR20110118611A (ko) 암의 치료를 위한 ｗｎｔ 신호전달 경로 억제제로서의 피리딘계 및 피리미딘계 화합물
EP0319429B1 (en) 9-Acylamino-tetrahydroacridine derivatives and memory enhancing agent containing said derivative as active ingredient
EP0397040A2 (en) N-heteroaryl-4-quinolinamines, a process for their preparation and their use as medicaments
US4804665A (en) Azaspiro compounds and their use
JP2001513749A (ja) ブラジキニン作動薬としてのキノリンおよびベンズイミダゾール誘導体
AU645707B2 (en) Piperidine derivatives
WO2007053394A1 (en) Kinase inhibitors
NZ328789A (en) 4-(3-alkoxy or cycloalkyloxy-4-methoxybenzyl)-1-(heteroaryl or aryl-carbonyl)piperidine derivatives; medicaments
HU198202B (en) Process for production of derivatives of 2-/4-buthilpiperasine-1-il/-piridin with antipsichotical effect
JP2003509494A (ja) ムスカリン拮抗薬
KR101132599B1 (ko) 아폽토시스 유도 효과를 갖는 인돌 유도체
US3847923A (en) N-(1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carbonyloxy)succinimide and glutarimide
JPH0597845A (ja) 縮合ジアゼピノン及びこれらの化合物を含む薬剤
EP3750893A1 (en) Dioxazoline compound, preparation method therefor, and uses thereof
JPH0545591B2 (cg-RX-API-DMAC7.html)
WO2004002956A2 (en) Asymmetric synthesis of amino-pyrrolidinones and a crystalline, free-base amino-pyrrolidinone
JPH07145055A (ja) コレシストキニン拮抗薬
KR20010013825A (ko) 파네실 단백질 전이효소를 억제하기에 유용한비스피리도-사이클로헵탄 화합물

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 19990413

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20000427

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20000427

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000